新浪登录
腾讯登录联邦政府奖励MRIGlobal1480万美元，用于传染性疾病的NGS平台研发
| 导读 | MRIGlobal23日宣布，其获得了一个为期三年，1480万美元的奖励，用于开发一个终端到终端的下一代测序系统，该系统主要用于传染性疾病的临床诊断。 |
该合同来自美国国防部的国防威胁降低部门，主要用于研发一种样品到测序的平台，该平台可以生成从血液，唾液以及其他临床样本中获得的细菌和病毒的高品质的全基因组序列。在一份申明中，该公司表示，该系统的目标，是能够从单一的样品中，鉴别出广泛的人类病原体，“特别是那些新型病原体和纳西没有快速诊断方法可以识别的病原体”。
MRIGlobal补充道，该技术将让临床医生将一个单一的样本发送到实验室，然后通过全基因组测序解释样品中的微生物，这是通过与已经开发的，能够造成传染性疾病的微生物数据库对比得出的。据MRIGlobal CEO Thomas Sack说，目前通过测序数据识别病原体的方法需要一个星期才能生成数据。而他们开发的技术，有望在24小时内就提供相关的数据。
通过系统产生的临床数据将提交给美国食品和药物管理局等监管机构进行批准，然后作为商业开发平台的一部分进行使用。
The contract from the Defense Threat Reduction Agency of the US Department of Defense is for the development of a sample-to-sequence platform that can generate high-quality whole-genome sequences of bacteria and viruses from blood, saliva, and other clinical samples, Kansas City, Mo.-based MRIGlobal said. The goal is a system that can identify a broad range of human pathogens from a single sample "with particular emphasis on emerging pathogens and those not identifiable by available rapid diagnostic methods," it said in a statement.
MRIGlobal added that the technology would enable clinicians to send a single sample to a laboratory for sequencing with genomes uncovered in the sample to be identified against a developed database of microorganisms that can cause infectious diseases. According to MRIGlobal CEO Thomas Sack, current methods for identifying pathogen sequencing data can take a week to generate data. The technology to be developed will provide answers within 24 hours, he said.
Clinical data generated by the system will be used as part of a submission to the US Food and Drug Administration for regulatory approval and then the commercial launch of the platform.
MRIGlobal补充道，该技术将让临床医生将一个单一的样本发送到实验室，然后通过全基因组测序解释样品中的微生物，这是通过与已经开发的，能够造成传染性疾病的微生物数据库对比得出的。据MRIGlobal CEO Thomas Sack说，目前通过测序数据识别病原体的方法需要一个星期才能生成数据。而他们开发的技术，有望在24小时内就提供相关的数据。
通过系统产生的临床数据将提交给美国食品和药物管理局等监管机构进行批准，然后作为商业开发平台的一部分进行使用。
MRIGlobal将提供技术分析，并选择与下一代测序和生物信息学相关的样品制备的组件。该公司也将负责系统设计和整合，以及测试，以及监管审查以及之后该系统的商业化。
原文：
MRIGlobal today announced it has been awarded a three-year, $14.8 million contract to develop an end-to-end next-generation sequencing system for the clinical diagnosis of infectious diseases.The contract from the Defense Threat Reduction Agency of the US Department of Defense is for the development of a sample-to-sequence platform that can generate high-quality whole-genome sequences of bacteria and viruses from blood, saliva, and other clinical samples, Kansas City, Mo.-based MRIGlobal said. The goal is a system that can identify a broad range of human pathogens from a single sample "with particular emphasis on emerging pathogens and those not identifiable by available rapid diagnostic methods," it said in a statement.
MRIGlobal added that the technology would enable clinicians to send a single sample to a laboratory for sequencing with genomes uncovered in the sample to be identified against a developed database of microorganisms that can cause infectious diseases. According to MRIGlobal CEO Thomas Sack, current methods for identifying pathogen sequencing data can take a week to generate data. The technology to be developed will provide answers within 24 hours, he said.
Clinical data generated by the system will be used as part of a submission to the US Food and Drug Administration for regulatory approval and then the commercial launch of the platform.
MRIGlobal will provide technology analysis and choose components associated with sample preparation, next-generation sequencing, and bioinformatics. The company will also be in charge of systems engineering and integration, as well as testing, ahead of regulatory reviews and the commercialization of the system post-contract, it said.（转化医学网360zhyx.com）
以上为转化医学网原创翻译整理。如需转载，请联系 info@360zhyx.com。
还没有人评论，赶快抢个沙发